F
Feitong Bio
Innovative biologic therapeutics for oncology and immunology
About Feitong Bio
Feitong Bio, also known as Sound Biopharmaceuticals, is a biopharmaceutical company focused on discovering and developing innovative biologic treatments for oncology and immunology. The company, co-founded by Dr. Qing Li in 2017, operates with advanced technology platforms for molecular biology, antibody screening, and protein engineering.
Dr. Li, who serves as CEO, earned his PhD in clinical immunology and completed postdoctoral training at Stanford University before founding Ascenta Biosciences in 2015. The management team includes CSO Dr. Zhong Wang, a former Amgen scientist and professor at Sun Yat-sen University, and Co-founder/CTO Dr. Fanxin Ma. The company is headquartered in Chengdu, China.
Sound Biopharmaceuticals' business model centers on the research, development, and global commercialization of antibody-based therapeutics. Key investors include Chengdu Bio-Town Investment, Richland Equities, and Sichuan Development Fund. The company has developed the ADICT bispecific technology platform and utilizes monoclonal antibody screening and optimization to build its pipeline.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- China
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
JCP Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Feitong Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Feitong Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.